Poster Abstract Session:
59. Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID


Presentations:
468
Diagnosis of Clinical Clostridium Difficile Infection: An Unmet Challenge
Neeti Vyas, MBBS, MPH; Rosemary C. She, M.D.; Neha Nanda, MD
Posters
  • C.diff poster.Final.pdf (349.4 kB)
  • 470
    Concomitant Antibiotic Use and Death Among a National Cohort of Veterans with Clostridium difficile Infection (CDI)
    Haley Appaneal, PharmD; Aisling Caffrey, PhD, MS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
    Posters
  • IDweek_2018_CDI - AU.pdf (540.4 kB)
  • 471
    Prevalence and characteristics of Clostridioides difficile infection in Bangladesh
    Amelia K. Sofjan, PharmD; M. Jahangir Alam, PhD; M. Aminul Islam, PhD; Kevin W. Garey, PharmD, M.S.
    472
    Prevalence, risk factors, and outcome of postoperative Clostridium difficile infection after orthopedic surgery
    Dong Youn Kim, MD; Yu-Mi Lee, MD; Young Jin Kim, MD; Misuk Lee, MD; Hee-Joo Lee, MD; Ki-Ho Park, MD
    473
    Molecular Typing of Clostridium difficile: Concordance between PCR-Ribotyping and Multilocus Sequence Typing (MLST)
    Xiong Wang, DVM, PhD; Stacy Holzbauer, DVM, MPH; Kelly Pung, BS; Maria Bye, MPH; Michelle Adamczyk, BS; Ashley Lyn Paulick, BS; Nicholas Vlachos, MS; Alice Guh, MD, MPH; Alison S. Laufer-Halpin, Ph.D.; Maria S. Karlsson, PhD; Dave Boxrud, MSc
    Posters
  • IDweekPoster-C.diffFinal.pdf (1.2 MB)
  • 474
    Temporal Trends of Inpatient C. difficile Infections within the Veterans Affairs Hospitals: A Bioinformatics Analysis of Nationwide Metadata from the Past Decade
    Zarchi Sumon, MD; Alan Lesse, MD, FIDSA; John Sellick, D.O., M.S., FIDSA, FSHEA; Kari Mergenhagen, Pharm.D., BCPS AQ-ID
    475
    Burden of Clostridium difficile Infection in South Carolina: A Population-Based Study
    Mariam Younas, MD; Julie Royer, MPH; Sharon Weissman, MD; Linda Bell, MD; Anton Maki Jr., M.D., MBA, FRCPC, FCAP, FACP; Katie Stilwell Waites, MPH; Sangita Dash, MD; Majdi N. Al-Hasan, MBBS
    Posters
  • Burden of CDI in SC.pdf (321.1 kB)
  • 476
    Comparison of Community-Associated Clostridium difficile Infections with other Reportable Enteric Pathogens, Minnesota, 2016
    Patrick Balius, BA; Maria Bye, MPH; Kirk Smith, DVM, PhD; Stacy Holzbauer, DVM, MPH
    Posters
  • IDWeek 2018 FINAL .pdf (282.7 kB)
  • 477
    Trends in the Incidence of Community-Associated and Healthcare-Associated Clostridium difficile Infections in Quebec over a 7-Year Period (2008-2015)
    Veronica Zanichelli, MD; Christophe Garenc, PhD; Jasmin Villeneuve, MD; Danielle Moisan, MD; Charles Frenette, MD, FSHEA; Yves Longtin, MD
    478
    Improving Acid Suppression Therapy to Reduce Hospital-Onset C. difficile infection (HO-CDI): Impact of a Novel Analytic Application
    Stephen Eppes, MD; Marci Drees, MD, MS; Donna Walsh, PharmD; Nicole Harrington, PharmD; Michael Winiarz, BS, MS; Anthony Gabriel, PharmD; Edward F. Ewen, MD
    479
    Trends in C. difficile Incidence, Mortality, and NAP1/027 Strain in the Population of Monroe County, NY
    Trupti Hatwar, MPH; Rebecca Tsay, MPH, MLS; Deborah Nelson, MSN, RN; Christina B. Felsen, MPH; Ghinwa Dumyati, MD, FSHEA
    480
    Reduction in Clostridium difficile Infection Rates Following a Prevention Collaborative in Orange County, California, 2014-2017
    Kyle Rizzo, MPH; Erin Garcia, MPH, CPH; Matthew Zahn, MD, FIDSA; Sarah H. Yi, PhD; Erin Epson, MD
    481
    Implementation of a Prospective, Pharmacist-Driven Clostridium difficile PCR Pre-Authorization Process to Optimize Appropriate Testing
    Erik LaChance, Pharm.D.; Jessica Miller, Pharm.D.; Imad Almanaseer, MD; Jay Watson, IP Surveillance Analyst; Robert Citronberg, MD; Leo Kelly, MD; Angelica Whaley, MS, MT(ASCP); Sarah M. Wieczorkiewicz, Pharm.D., BCPS AQ-ID
    482
    Association between Socioeconomic Status Factors and Incidence of Community-Associated Clostridium difficile Infection Utilizing Factor Analysis— United States, 2014–2015
    Kimberly Skrobarcek, MD; Yi Mu, PhD; Jennifer Ahern, PhD; Zintars Beldavs, MS; Geoff Brousseau, MPH; Ghinwa Dumyati, MD, FSHEA; Monica M. Farley, MD, FIDSA; Stacy Holzbauer, DVM, MPH; Marion A. Kainer, MBBS, MPH; James I. Meek, MPH; Rebecca Perlmutter, MPH; Erin C. Phipps, DVM, MPH; Lisa G. Winston, MD; Alice Y. Guh, MD, MPH
    483
    Clinical Characteristics of Military Trauma Patients with Clostridium difficile Infections
    Sarah Schall, MD; Ping Li, MS; Teresa Merritt, BS; Leigh Carson, MS; Timothy J. Whitman, DO; Joseph L. Petfield, MD; David R. Tribble, MD, DrPH; Dana M. Blyth, MD
    484
    A Severity Score for Predicting In-Hospital Death in Patients with Clostridium difficile Infection: A Hospital-Based Cohort Study
    Hsiu-Yin Chiang, PhD; Han-Chun Huang, MS; Chih-Wei Chung, MS; Yi-Chun Yeh, BSN; Ni Tien, PhD; Hsiu-Shan Lin, MS; Chin-Chi Kuo, MD, PhD
    485
    On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)
    Vanessa Stevens, PhD; Jian Ying, PhD; Molly Leecaster, PhD; Brian Sauer, PhD; Michael Rubin, MD, PhD, FIDSA
    487
    Severity and clinical outcomes of Clostridium difficile infection based on Toxin B Assay Results
    Jorge Jo Kamimoto, MD; Sandra Susanibar, MD; Meera Mohan, MD; Piroon Jenjaroenpun, PHD; Krishnan Gayathri, MD; Juan Carlos Rico, MD; Mary J Burgess, MD; Ruslana Tytarenko, MS; Nicole Emery, BS M(ASCP); Eric Rosenbaum, MD, MPH; Brian Walker, PHD; Intawat Nookaew, PHD; Atul Kothari, MD
    Posters
  • IDSA-2018-Poster-Final.pdf (739.9 kB)
  • 488
    Oral Vancomycin plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
    Ana Vega, PharmD; Teri Hopkins, PharmD, BCPS; Emily Heil, PharmD, BCPS-AQID; Jennifer Johnson, PhD; Surbhi Leekha, MBBS, MPH; Kimberly Claeys, PharmD, BCPS
    489
    Validation of the SHEA/IDSA severity criteria to predict poor outcomes among inpatients and outpatients with Clostridium difficile infection
    Vanessa Stevens, PhD; Makoto Jones, MD, MS; Richard E. Nelson, PhD; Karim Khader, PhD; Matthew Samore, MD, FSHEA; Michael Rubin, MD, PhD, FIDSA
    490
    Comparison of Clostridium difficile Infection Outcomes by Diagnostic Testing Method
    Alice Guh, MD, MPH; Kelly Hatfield, MSPH; Lisa G. Winston, MD; Brittany Martin, MPH; Helen Johnston, MPH; Geoff Brousseau, MPH; Monica M. Farley, MD, FIDSA; Lucy E. Wilson, MD, ScM; Rebecca Perlmutter, MPH; Erin C. Phipps, DVM, MPH; Ghinwa Dumyati, MD, FSHEA; Deborah Nelson, MSN, RN; Trupti Hatwar, MPH; Marion A. Kainer, MBBS, MPH; L. Clifford McDonald, MD
    491
    Clinical Manifestations and Outcomes of Clostridium difficile Infection in Long Term Care Patients: An 8-Year Retrospective Cohort Study.
    Suganya Chandramohan, MD; Amar Krishna, MD; Parminder Virdi, MD; Jordon Polistico, MD; Nikhila Thammineni, MD; Anupamdeep Singh Mehar, MD; Angad Singh Gill, MD; Aleena Saleem, MD; Ibtehaj Javed, MD; Dania Qaryoute, MD; Daniel Deporre, MS; Pingping Zhang, MS STATISTICS; Kirstin Heinrich, MPH; Elisa Gonzalez, MSc; Teena Chopra, MD, MPH
    492
    Long term Outcomes of Clostridium difficile Infection among Medicare Beneficiaries
    Kelly M. Hatfield, MSPH; James Baggs, PhD; Lisa G. Winston, MD; Erin Parker, MPH; Brittany Martin, MPH; James I. Meek, MPH; Danyel Olson, MS, MPH; Monica M. Farley, MD, FIDSA; Andrew Revis, MPH; Stacy Holzbauer, DVM, MPH; Maria Bye, MPH; Lucy Wilson, MD, ScM; Rebecca Perlmutter, MPH; Erin C. Phipps, DVM, MPH; Rebecca Pierce, PhD, MS, BSN; Valerie L.S. Ocampo, RN, MIPH; Marion A. Kainer, MBBS, MPH; Miranda Smith, MPH; L. Clifford McDonald, MD; John A. Jernigan, MD, MS; Alice Guh, MD, MPH
    493
    Development of a simple Clostridium difficile infection clinical risk prediction tool for medical inpatients
    Winnie Ma, B.Sc.(Pharm), ACPR; Torey Lau, B.Sc.(Pharm), ACPR; Vivian Leung, B.Sc.(Pharm), Pharm.D, ACPR; Victoria Su, B.Sc.(Pharm), Pharm.D, ACPR; Joseph Puyat, PhD, M.Sc, MA (Psych); Stephen Shalansky, B.Sc.(Pharm), ACPR, Pharm.D
    Posters
  • CDI Risk Tool Poster.pdf (620.6 kB)
  • 494
    Use of a Clinical Prediction Tool to Predict Clostridium difficile Infection
    Marten Hawkins, MPH; Michael Baumgartner, BS Neurobiology; Danielle VanBeckum, BS, MS; Julia Buck, BS, BA; Crystal Holley, BS
    Posters
  • Conference Poster.pdf (441.5 kB)
  • 495
    Predictors of C. difficile Infection and Impact of Primary Prophylaxis among Asymptomatic C. difficile Colonized Patients: A Cross Sectional Study
    Dominic Poirier, MD; Philippe Gervais, MD; Margit Fuchs, PhD; Jean-Francois Roussy, MD; Bianka Paquet-Bolduc, MPA; Sylvie Trottier, MD, PhD; Jean Longtin, MD; Vivian Loo, MD; Yves Longtin, MD
    496
    Secondary Prophylaxis for Clostridium difficile infection - A Physician Practice Assessment
    Mindy Sampson, DO; Kristen Zeitler, PharmD; Jasmine R Marcelin, MD; Sadaf Aslam, MD; John Sinnott, MD, FACP, FIDSA, FSHEA; Seetha Lakshmi, MD
    497
    Identification of Patients at Risk of Clostridium difficile Infection for Enrollment in Vaccine Clinical Trials
    Vanessa Stevens, PhD; Ellyn Russo, MS; Yinong Young-Xu, ScD, MS, MA; Molly Leecaster, PhD; Yue Zhang, PhD; Chong Zhang, MS; Holly Yu, MSPH; Bing Cai, PhD; Elisa Gonzalez, MSc; Dale N Gerding, MD, FIDSA; Jody Lawrence, MD; Matthew Samore, MD, FSHEA
    498
    Molecular Epidemiology of C. difficile within a Community Hospital: A Pilot for a Regional Survey
    Nicholas Turner, MD; Bobby Warren, MPS; Vance G. Fowler Jr., MD; Deverick J. Anderson, MD, MPH, FIDSA, FSHEA
    Posters
  • C diff Molec Epi DRH FINAL.pdf (691.6 kB)
  • 499
    Determining Risk of Clostridium difficile Using Electronic Health Record (EHR) Data
    Marci Drees, MD, MS; Edward F. Ewen, MD; Michael Winiarz, BS, MS; Stephen Eppes, MD
    500
    Efficacy of 30-Day Fidaxomicin for Treatment of Acute Clostridium difficile Infection with History of Multiple Recurrences
    Christine Lee, MD, FRCPC; Minahz Habib, BSc; Christiana Kim, BSc; Peyman Goldeh, B. Eng; Salaheddin Abouanaser, MD, FRCPC; Peter Kim, PhD
    501
    Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single Arm Study in Outpatient Infusion Centers
    Richard L. Hengel, MD; Timothy E. Ritter, MD; Ramesh V. Nathan, MD, FIDSA; Lucinda J. Van Anglen, PharmD; Claudia P. Schroeder, PharmD, PhD; Stephen Marcella, MD, MPH; Kevin W. Garey, PharmD, M.S.
    502
    Enhanced Sporulation and Vancomycin Resistance Associated with Clostridium difficile from Recurrent Infections.
    Laura E. Tijerina-Rodriguez, MSc; Adrián Martínez-Meléndez, MSc; Licet Villarreal-Treviño, PhD; Rayo Morfín-Otero, MD, PhD; Adrian Camacho-Ortiz, MD, PhD; Simon D. Baines, PhD; Eduardo Rodríguez-Noriega, MD, PhD; Elvira Garza-González, PhD
    Posters
  • Poster 502 IDWEEK LETR.pdf (730.0 kB)
  • 504
    Change in Clostridium difficile Strain Type Distribution after Implementation of Diagnostic Stewardship
    Tracy McMillen, BS; Hoi Yan Chow, MS; Anoshé Aslam, MPH; Jennifer Brite, DPH; N. Esther Babady, Ph.D; Mini Kamboj, MD
    509
    Spatio-Temporal Clustering of CDI Cases at the University of Iowa Hospitals and Clinics
    Shreyas Pai, B.Tech; Sriram Pemmaraju, PhD; Philip M. Polgreen, MD; Alberto Maria Segre, PhD; Daniel Sewell, PhD
    510
    First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
    M. Jahangir Alam, PhD; Khurshida Begum, PhD; Jacob McPharson, BS; Julie Miranda, BS; Feroz Hossain, MS; Kelley Poblete, BS; Kevin W. Garey, PharmD, M.S.
    511
    What is the Current State of Patient Education after Clostridium difficile Infection?
    Christina DeBenedictus, BA; Jacob John, APRN; Michelle Hecker, MD; Curtis J. Donskey, MD; Payal K. Patel, MD, MPH
    512
    Tracking the use of soap and sanitizer for hand hygiene after caring for Clostridium difficile patients
    Bryan Knepper, MPH, MS, CIC; Sara Reese, PhD, MPH, CIC, FAPIC; Amber Miller, MSN, RN, CIC, CSPDT; Heather Young, MD
    Posters
  • CDIFF soap eHH poster_final.pdf (213.9 kB)
  • 514
    The Effect of Probiotics on the Incidence of Clostridium difficile
    Temima Saltzman, PharmD; Sharon Blum, PharmD; Burke A. Cunha, MD, FIDSA, FSHEA; Melissa Fazzari, PhD; Shirley Chung, PharmD candidate
    Posters
  • ID week poster 9.6.18.pdf (583.3 kB)
  • 516
    Implementation of a probiotic for the primary prevention of hospital-onset Clostridium difficile infection
    Kati Shihadeh, PharmD; Heather Young, MD; Bryan Knepper, MPH, MS, CIC; Robert Tapia, CPhT; Timothy C. Jenkins, MD
    Posters
  • 516_IDWPOSTER final.pdf (508.2 kB)
  • 518
    Modeling the Potential Impact of Administering Vaccines against Clostridium difficile infection to Individuals in Healthcare Facilities
    Damon Toth, PhD; Matthew Samore, MD, FSHEA; Karim Khader, PhD; Justin O'Hagan, ScD; Holly Yu, MSPH; Alvaro Quintana, MD; David L. Swerdlow, MD
    519
    Longer Length of Antibiotic Therapy for Community-Acquired Pneumonia and Risk of Clostridium difficile Infection
    Sarah H. Yi, PhD; Sujan C. Reddy, MD; Sophia V. Kazakova, MD, MPH, PhD; Kelly M. Hatfield, MSPH; James Baggs, PhD; Alice Y. Guh, MD, MPH; Preeta K. Kutty, MD; Lauri A. Hicks, DO; Arjun Srinivasan, MD; L. Clifford McDonald, MD; John A. Jernigan, MD, MS
    520
    Reducing Inappropriate Clostridium difficle Testing by Empowering Nurses
    Jennifer LeRose, MPH; Amar Krishna, MD; Suganya Chandramohan, MD; Michelle Bartholomew, BS; Margaret Turner, M.Ed., CIC, RN; Nancy Baran, MS, CIC; Thomas Chevalier, RN, BSN, CIC; Judy Moshos, MT (ASCP), CIC; Samyah Mogalli, MHSA, MT(ASCP); Lynn Semproch, MPH, CIC; Teena Chopra, MD, MPH
    Posters
  • RN Driven Algorithm HO CDI.pdf (369.8 kB)
  • 521
    Clostridium difficile Timeout: A Nurse – Driven Protocol to Optimize Testing Stewardship
    Cindy Hou, DO, MA, MBA, FACOI; Nikunj Vyas, PharmD, BCPS; Lea Ann Kellum, MSN, RN, CCRN, CEN; Mary Miller, RN, BSN, CIC; Ann Marie Flory, MSN, RN, NE-BC; Shereef Ali, PharmD, BCPS, BCCCP
    Posters
  • IDWeek Poster CDTfinalPDF.pdf (919.3 kB)
  • 522
    Impact of a multicomponent intervention bundle on healthcare facility-onset Clostridium difficile rates
    Ann Keegan, BSN, RN, CIC; Kelli Cole, PharmD, BCPS; Melissa Ahrens, MPH, CIC; Mark Eckhart, MPH, LPTA, CIC; Geehan Suleyman, MD
    523
    Use of Whole-Genome Sequencing to Guide a C. difficile Diagnostic Stewardship Program
    Kunal Jakharia, MBBS; Ghassan Ilaiwy, MD; Siobhan Moose, RN; Masahi Waga, -; Joel McAlduff, MD; Lynne Karanfil, RN, MA, CIC, FAPIC; Patrick Mcgann, PhD; Glenn Wortmann, MD
    Posters
  • IDSA 5.0.pdf (1.0 MB)
  • 524
    The Journey to Implement a Computerized Clinical Decision Support (CDS) Tool to Improve Testing for Clostridium difficile Infection (CDI)
    Jeanmarie Mayer, MD; Jamie Fendler, RN, CIC; Tristan T. Timbrook, PharmD, MBA, BCPS; Claire Ciarkowski, MD; Emily Spivak, MD, MHS
    525
    The Impact of Switching to Molecular Testing on Clostridium difficile Infection Rates: Large-Scale Assessment Using an Interrupted Time Series Poisson Regression Approach
    Tiago Barbieri Couto Jabur, BS; Iulian Ilies, PhD; Arthur W. Baker, MD, MPH; Deverick J. Anderson, MD, MPH, FIDSA, FSHEA; James Benneyan, PhD
    526
    An EMR-based diagnostic stewardship intervention for GI mPCR aimed at reducing inappropriate C. difficile tests
    Margaret E. Newman, MD; Emily Landon, MD; Allison Bartlett, MD, MS; Rachel Marrs, DNP, RN, CIC; Alexandra Seguin, BSN, RN; Cynthia Murillo, M(ASCP), CIC; Kathleen G. Beavis, MD; Jessica P. Ridgway, MD, MS
    527
    New Robust Antimicrobial Stewardship Program (ASP) Results in Reduction of Clostridium difficile 30-Day Readmission
    Jennifer Anthone, PharmD; Anum Abbas, MD; Bryan Alexander, Bryan, Pharm.D.; Dayla Boldt, PharmD; Sumaya Ased, PharmD; Cassara Carroll, PharmD; Stephen Cavalieri, PhD; John Horne, MD; Manasa Velagapudi, MD; Carrie Valenta, MD; Giri Andukuri, MD; Richard Albert Paguia, MD; Michael Petzar, MD; Thamer Kassim, MD; Elizabeth George, MD, MPH; Eric Magliulo, BS; Christopher Destache, PharmD; Renuga Vivekanandan, MD
    528
    Lab Stewardship for Clostridium difficile Testing Improves Appropriate Testing While Decreases Unnecessary Testing and Saves Laboratory Resources While Dramatically Helping to Reduce C diff Standardized Infection Ratios (SIR)
    Jorge P Parada, MD, MPH; Dominique Wright, MPH; Sylvia Suarez-Ponce, BSHCL, RN, CIC; Elaine Trulis, MS, BSN, RN, CIC; Purisima Linchangco, MD, MPH, CIC; Ayat Abuihmoud, MS, CIC; Herminia Pua, RN, BSN, CIC; Melissa Green, BA; Heather Hedlund, RN; Kevin R Smith, MD; Amanda Harrington, Ph.D.
    529
    Overdiagnosis of Clostridioides difficile with a Multiplex PCR Panel
    Vaneet Arora, MD, MPH, D(ABMM); Donna R. Burgess, RPh; Julie A. Ribes, MD, PhD; Sarah Cotner, PharmD, BCPS; Katie L. Wallace, PharmD, BCPS; Derek Forster, MD
    531
    Reducing Inappropriate Hospital-Acquired Clostridium difficile Diagnoses.
    Robert Duncan, MD, MPH, FIDSA, FSHEA; Jane Eyre-Kelly, RN, CIC; Jose Cartagena, MT, CIC; Melissa Gawlick, MPH; Rosemarie Delacy, RN; Andrew Villanueva, MD
    532
    Recurrent C. difficile in Children: Not Easy to Cure
    Philip Lee, Pharm D.; Olga Aroniadis, MD; Sarah Noble, M4 Medical Student; Fatimah Rimawi, M4 Medical Student; David Goldman, M.D
    533
    Scaling Pediatric Access to Fecal Microbiota Transplantation in the United States: A Time-series Geospatial Analysis
    Pratik Panchal, MD MPH; Stacy Kahn, MD; Caroline Zellmer, BS; Zain Kassam, MD MPH; Majdi Osman, MD MPH; Jessica Allegretti, MD, MPH; Monica Seng, AB; Shrish Budree, MD
    534
    Clostridium difficile reduction: An agent-based simulation modeling approach to evaluating intervention comparative effectiveness at pediatric hospitals
    Anna Barker, PhD; Elizabeth Scaria, BE; Oguzhan Alagoz, PhD; Ajay Sethi, PhD, MHS; Nasia Safdar, MD, PhD
    Posters
  • Peds ABM.pdf (604.7 kB)
  • 535
    Transmission of Clostridium Difficile (CD) from patients ≤ 2 years of age in a Pediatric Oncology setting
    Elizabeth Robilotti, MD, MPH; Hoi Yan Chow, MS; Tracy McMillen, BS; Weihua Huang, PhD; Donald Chen, MD; N. Esther Babady, Ph.D; Mini Kamboj, MD
    536
    Clostridium difficile Colonization in the First Year of Life.
    Jason A. Clayton, MD, PhD; Jennifer Cadnum, B.S.; Shelly Senders, MD; Curtis J. Donskey, MD; Philip Toltzis, MD
    537
    Engaging the bedside nurse in reducing Clostridium difficile infection through an innovative patient care rounding program
    James Newton Jr., MD, FACP, FIDSA; Julie Gregory, RN; Susan Benedetti, BA, RN, CIC; Jamie Huneycutt, BSN, RN, CIC; Rebecca Cowie, APRN, RN, ACNS-BC, CCRN

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.